Freenome Holdings Inc (Freenome) develops and provides a medical arti?cial intelligence (AI) platform which to detect cancer at its earliest stages. The company provides cell-free (cf) biomarkers which include cfDNA, Provides insights into immune response and tumor heterogeneity, cfRNA, Records which genes were actively expressed at the time of apoptosis, and Proteins, Identi?es proteins associated with speci?c tumor types. Freenome is utilizing an AI genomics platform and developing noninvasive blood tests to detect early-stage cancer and improve precision oncology treatments. The company collaborated with pharmaceutical companies, integrated health systems and academic institutions to use its AI genomics platform for improving cancer treatment. It has partnerships with Founders Fund, Google Ventures, Polaris and Andreessen Horowitz. Freenome is headquartered in South San Francisco, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Freenome Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Freenome Inc Company Overview
- Freenome Inc Company Snapshot
- Freenome Inc Pipeline Products and Ongoing Clinical Trials Overview
- Freenome Inc - Pipeline Analysis Overview
- Freenome Inc - Key Facts
- Freenome Inc - Major Products and Services
- Freenome Inc Pipeline Products by Development Stage
- Freenome Inc Ongoing Clinical Trials by Trial Status
- Freenome Inc Pipeline Products Overview
- Artificial Intelligence Based Companion Diagnostics - Breast Cancer
- Artificial Intelligence Based Companion Diagnostics - Breast Cancer Product Overview
- Artificial Intelligence Based Companion Diagnostics - Colorectal Cancer
- Artificial Intelligence Based Companion Diagnostics - Colorectal Cancer Product Overview
- Artificial Intelligence Based Companion Diagnostics - Colorectal Cancer Clinical Trial
- Artificial Intelligence Based Companion Diagnostics - Lung Cancer
- Artificial Intelligence Based Companion Diagnostics - Lung Cancer Product Overview
- Artificial Intelligence Based Companion Diagnostics - Lung Cancer Clinical Trial
- Artificial Intelligence Based Companion Diagnostics - Pancreatic Cancer
- Artificial Intelligence Based Companion Diagnostics - Pancreatic Cancer Product Overview
- Artificial Intelligence Based Companion Diagnostics - Pancreatic Cancer Clinical Trial
- Artificial Intelligence Based Companion Diagnostics - Prostate Cancer
- Artificial Intelligence Based Companion Diagnostics - Prostate Cancer Product Overview
- Freenome Inc - Key Competitors
- Freenome Inc - Key Employees
- Freenome Inc - Locations And Subsidiaries
- Head Office
- Recent Developments
- Freenome Inc, Recent Developments
- Mar 28, 2023: Freenome adds Renown Health as partner for the Sanderson Study
- Jan 18, 2023: Freenome partners with Geisinger for the Sanderson study
- Apr 11, 2022: Freenome presents research that highlights the significance of detecting adenomas in any test that screens for colorectal cancer
- Apr 10, 2021: Freenome presents data revealing signatures of immune checkpoint inhibitor treatment response found to be common across kidney, melanoma, and lung cancers
- Jul 15, 2020: Freenome Holdings chooses SYSPRO ERP to help enable next-generation early cancer detection
- Jan 23, 2020: Freenome announces encouraging performance data for Its multiomics blood test to detect early-stage colorectal cancer in a prospective, multi-center clinical study
- Jul 25, 2019: Freenome raises $160m to advance cancer diagnostic test
- Apr 30, 2019: Freenome bolsters scientific leadership, naming Genomic-Medicine Pioneer, Jimmy Lin, as new chief scientific officer
- Oct 09, 2018: Freenome Unveils Promising Early Data on Colorectal Cancer Screening Test at American College of Gastroenterology Annual Meeting
- Jul 12, 2018: Freenome’s IMPACT Advisory Board Brings Strategic Insight and Real-World Experience to AI-Genomics Cancer Tests
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Freenome Inc Pipeline Products and Ongoing Clinical Trials Overview
- Freenome Inc Pipeline Products by Equipment Type
- Freenome Inc Pipeline Products by Indication
- Freenome Inc Ongoing Clinical Trials by Trial Status
- Freenome Inc, Key Facts
- Freenome Inc, Major Products and Services
- Freenome Inc Number of Pipeline Products by Development Stage
- Freenome Inc Pipeline Products Summary by Development Stage
- Freenome Inc Ongoing Clinical Trials by Trial Status
- Freenome Inc Ongoing Clinical Trials Summary
- Artificial Intelligence Based Companion Diagnostics - Breast Cancer - Product Status
- Artificial Intelligence Based Companion Diagnostics - Breast Cancer - Product Description
- Artificial Intelligence Based Companion Diagnostics - Colorectal Cancer - Product Status
- Artificial Intelligence Based Companion Diagnostics - Colorectal Cancer - Product Description
- Artificial Intelligence Based Companion Diagnostics - Colorectal Cancer - Prevention of Colorectal Cancer Through Multiomics Blood Testing
- Artificial Intelligence Based Companion Diagnostics - Colorectal Cancer - The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
- Artificial Intelligence Based Companion Diagnostics - Lung Cancer - Product Status
- Artificial Intelligence Based Companion Diagnostics - Lung Cancer - Product Description
- Artificial Intelligence Based Companion Diagnostics - Lung Cancer - The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
- Artificial Intelligence Based Companion Diagnostics - Pancreatic Cancer - Product Status
- Artificial Intelligence Based Companion Diagnostics - Pancreatic Cancer - Product Description
- Artificial Intelligence Based Companion Diagnostics - Pancreatic Cancer - The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
- Artificial Intelligence Based Companion Diagnostics - Prostate Cancer - Product Status
- Artificial Intelligence Based Companion Diagnostics - Prostate Cancer - Product Description
- Freenome Inc, Key Employees
- Glossary
- Freenome Inc Pipeline Products by Equipment Type
- Freenome Inc Pipeline Products by Development Stage
- Freenome Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Exosome Diagnostics Inc
- Genomic Expression Inc
- Genomic Health Inc
- Genomic Health Inc
- Exosome Diagnostics Inc
- Genomic Expression Inc
